Morgan Jacqueline M, Lurain John R
John I. Brewer Trophoblastic Disease Center, Northwestern University Feinberg School of Medicine, 250 East Superior Street, Suite 05-2168, Chicago, IL 60611, USA.
Curr Oncol Rep. 2008 Nov;10(6):497-504. doi: 10.1007/s11912-008-0075-y.
Gestational trophoblastic neoplasia (GTN) includes invasive mole, choriocarcinoma, and placental site trophoblastic tumors. The overall cure rate in treating these tumors currently exceeds 90%. Thorough evaluation and staging allow selection of appropriate therapy that maximizes chances for cure while minimizing toxicity. Nonmetastatic (stage I) and low-risk metastatic (stages II and III, World Health Organization score < 7) GTN can be treated with single-agent chemotherapy, resulting in a survival rate approaching 100%. High-risk metastatic GTN (stage IV, WHO score > or = 7) requires initial multiagent chemotherapy with or without adjuvant radiation and surgery to achieve a survival rate of 80% to 90%.
妊娠滋养细胞肿瘤（GTN）包括侵蚀性葡萄胎、绒毛膜癌和胎盘部位滋养细胞肿瘤。目前治疗这些肿瘤的总体治愈率超过90%。全面的评估和分期有助于选择合适的治疗方法，在将毒性降至最低的同时，最大限度地提高治愈几率。非转移性（I期）和低风险转移性（II期和III期，世界卫生组织评分<7）GTN可采用单药化疗，生存率接近100%。高风险转移性GTN（IV期，世界卫生组织评分>或 = 7）需要初始联合化疗，可联合或不联合辅助放疗和手术，以达到80%至90%的生存率。
